Arizona Gold & Silver Inc (TSX-V:AZS, OTCQB:AZASF) announced it has acquired approximately 300 acres of land intended for possible leach pad or tailings disposal use in support of future development at the Philadelphia gold project in northwestern Arizona.
The land was secured through claim staking and carries no obligations beyond the payment of annual maintenance fees to the US government, the company said on Monday.
Plug Power (NASDAQ:PLUG) shares surged after the company announced strong preliminary revenue results for the first quarter of 2025 and the signing of a significant $525 million secured credit facility with Yorkville Advisors.
The company, which is developing green hydrogen and fuel cell technologies, said it expects first quarter revenue in the range of $130 million to $134 million, in line with the analyst consensus of $131.6 million.
Medicus Pharma (NASDAQ:MDCX) announced that it has entered into a binding letter of intent to acquire Antev, a clinical-stage biotechnology firm developing a first-in-market product Teverelix for acute urinary retention (AUR) and high cardiovascular risk prostate cancer.
Teverelix, a next-generation GnRH antagonist, targets the prevention of recurrent AUR in males aged 45 years and older with benign prostate hyperplasia.
A sharp decline in childhood vaccination rates could open the door to a resurgence of measles and other long-eliminated diseases in the United States, according to new research published Thursday in JAMA.
The study warns that even at current immunization levels, the country may no longer be shielded from the return of measles as a regularly circulating virus.
Shares in Petro Matad Limited (AIM:MATD, OTC:PRTDF) rose on Monday as it inked an oil sales agreement with PetroChina Daqing Tamsag, for the production from Block XX in Mongolia.
Covering storage, processing, transport and export of crude oil the agreement enables the monetisation of the Heron 1 well, including past production between 24 October 2024 and 31 March 2025.
KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF) has confirmed that BCM Group has joined the Tulu Kapi Gold project syndicate.
BCM is set to act as 'Preferred Mining Contractor', subject to due diligence and final approvals.
European Metals Holdings Ltd (AIM:EMH, ASX:EMH, OTCQX:EMHLF) rocketed in Monday’s early deals after announcing final approval for a $36 million (CZK 800 million) grant from the European Union’s Just Transition Fund.
The grant funding for the Cinovec Project in the Czech Republic, remains subject to submission of an environmental impact assessment (EIA) by 31 December 2025 and its approval by 30 June 2026.
80 Mile PLC (AIM:80M, OTCQB:BLLYF) has inked a deal with March GL, a private US firm, to fund and drill two exploration wells at the Jameson gas and liquids project in East Greenland.
March GL will finance 100% of the drilling costs. Upon completing the first hole, March GL will earn a 50% interest, a second well would increase its stake to 70%.
Ananda Pharma Plc (AQSE:ANA, OTCQB:ANANF), the UK biopharmaceutical company, has received acknowledgement from Australia’s Therapeutic Goods Administration for its first clinical trial of a cannabidiol (CBD) drug, allowing the study to proceed under the country’s Clinical Trial Notification scheme.
The study will assess MRX1, a high-purity CBD formulation developed to treat chronic inflammatory pain.
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the UK liquid biopsy specialist, has unveiled new data showing its experimental HER2-CTC blood test delivers high sensitivity and specificity, bolstering its development programme for the cancer assay.
The results, to be presented at the American Association for Cancer Research meeting in Chicago, confirm that the test can detect HER2-positive circulating tumour cells (CTCs) from a simple blood sample with over 98% accuracy.
Cyprium Metals Ltd, a copper developer focused on recommencing production at the Nifty Copper Complex in the Paterson region of Western Australia, has advised that the proposed divestment of its Cue Project to Q Resources Pty Ltd, as announced on March 21 2025, has been cancelled by mutual agreement.
"As announced on April 23 2025, the company has regained 100% control of the Paterson Exploration Project. This necessitates a further review of strategy with respect to non-core greenfield exploration assets. Whilst this strategy review is ongoing, the Company has decided to retain the Cue Project and cancel the proposed transaction with Q Resources.
Livium Ltd secured a significant new recycling agreement with Sell & Parker Pty Ltd valued at more than A$5 million, in what could be the company's largest ever recycling contract. Executed after the end of the March quarter, the agreement is anticipated to deliver revenues of approximately A$3 million over the next 12 months, equivalent to 45% of Livium’s total revenues for financial year 2024.
The three-year agreement positions Livium to deliver recycling services for project-related materials, reinforcing the company's credentials as a recycler operating to high governance and safety standards. First volumes are expected in May 2025, with consistent deliveries extending into financial years 2026 and 2027. Livium does not anticipate any material changes to its operating costs under the agreement, with an increase in gross profit expected.
Recce Pharmaceuticals Ltd has signed a Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID), backed by funding from the Defense Threat Reduction Agency (DTRA).
The collaboration with USAMRIID further strengthens Recce’s partnerships with US government agencies to address global threats posed by antimicrobial resistance and biological warfare agents.